1.

Record Nr.

UNINA9910954475903321

Titolo

Neuroscience biomarkers and biosignatures : converging technologies, emerging partnerships : workshop summary / / Miriam Davis, Sarah Hanson, Bruce Altevogt, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Board on Health Sciences Policy, Institute of Medicine of the National Academies

Pubbl/distr/stampa

Washington, D.C., : National Academies Press, 2008

ISBN

9786611300241

9780309178280

0309178282

9781281300249

1281300241

9780309108904

030910890X

Edizione

[1st ed.]

Descrizione fisica

xi, 115 p. : ill

Altri autori (Persone)

DavisMiriam (Medical writer)

HansonSarah L <1980-> (Sarah Lynn)

AltevogtBruce M

Disciplina

612.8

Soggetti

Biochemical markers

Neurosciences

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Bibliographic Level Mode of Issuance: Monograph

Nota di bibliografia

Includes bibliographical references.

Nota di contenuto

Biomarkers and biosignature principles -- Potential tools for biomarker and biosignature development -- Psychiatric tools and drug addiction disorders -- Neurological and eye diseases.

Sommario/riassunto

Biomarkers, or biological markers, are quantitative measurements that offer researchers and clinicians valuable insight into diagnosis, treatment and prognosis for many disorders and diseases. A major goal in neuroscience medical research is establishing biomarkers for disorders of the nervous system.  Given the promising potential and necessity for neuroscience biomarkers, the Institute of Medicine Forum on Neuroscience and Nervous System Disorders convened a public



workshop and released the workshop summary entitled Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships.  The workshop brought together experts from multiple areas to discuss the most promising and practical arenas in neuroscience in which biomarkers will have the greatest impact. The main objective of the workshop was to identify and discuss biomarker targets that are not currently being aggressively pursued but that could have the greatest near-term impact on the rate at which new treatments are brought forward for psychiatric and neurological disorders.